DNA vaccine for liver cancer after curative surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a DNA-based vaccine called NWRD06 to lower the risk of liver cancer returning after a curative surgery or ablation. It is for people with a specific protein on their cancer cells and good liver function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with hepatocellular carcinoma (liver cancer) and your tumor tested positive for a marker called GPC3.
- Your cancer is at an early or moderate stage (BCLC A or B, or CNLC Ib to IIIa).
- You had successful surgery or ablation to remove the cancer within the past 12 weeks, and a recent scan shows no remaining cancer in the liver or elsewhere.
- You have good liver function (Child-Pugh score of A or B up to 7) and are in reasonably good health (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) combined with a PD-1 inhibitor to prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have a high risk of recurrence.
This trial tests an mRNA vaccine for people with liver cancer who are waiting for a liver transplant. The vaccine is given to help control the cancer while they wait.
This trial tests a new combination of two drugs (WGc-0201 plus Tislelizumab) to help prevent liver cancer from coming back after you've had surgery or ablation. It is for people with hepatitis B who are at high risk for recurrence.
This trial tests a new way to find and treat liver cancer that cannot be removed by surgery. First, a special dye (RYZ811) is used to see if your cancer cells have a marker called GPC3. If they do, you may receive a targeted radiation treatment (RYZ801) that seeks out those cells. This trial is for people whose liver cancer has grown despite receiving at least one prior therapy.
This trial tests a new drug that combines two immunotherapy approaches (PD-1 and IL-2) given before surgery to treat hepatocellular carcinoma (liver cancer) that has come back 3 months to 2 years after your first surgery. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This study tests whether adding two immunotherapy drugs (durvalumab and tremelimumab) plus radiation before surgery works better than radiation alone before surgery for people with resectable liver cancer. It's for those with a single tumor (or a few small nearby spots) that hasn't spread.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.